On Jun 21, 2008, at 5:32 PM, Day Sutton wrote:
I have a friend diagnosed with "pre-parkinsons", and another with the
full blown thing.
Day- I don't know about treating it with CS, but I gave my father
Essiac extract when he was bedridden, could no longer talk
intelligibly, and had bladder cancer. He started being able to speak
clearly enough to be understood. At that point he caught a very nasty
bronchitis and died from it so I didn't find out how much he might have
improved. Another thing I've heard of trying is LDN-
http://www.lowdosenaltrexone.org/ldn_and_ai.htm
www.ldninfo.org
LDN and Autoimmune Disease
In Brief
There is growing recognition in the scientific community that
autoimmune diseases result from immunodeficiency, which disturbs the
ability of the immune system to distinguish "self" from "non-self". The
normalization of the immune system induced by LDN makes it an obvious
candidate for a treatment plan in such diseases.
The experience of people who have autoimmune diseases and who have
begun LDN treatment has been remarkable. Patients with diagnoses such
as systemic lupus, rheumatoid arthritis, Behcet's syndrome, Wegener's
granulomatosis, bullous pemphigoid, psoriasis, and Crohn's disease have
all benefited.
Because LDN clearly halts progression in multiple sclerosis, its use
has been more recently extended to other neurodegenerative diseases,
such as Parkinson's disease and amyotrophic lateral sclerosis (ALS or
Lou Gehrig's disease) whose etiology remains unknown but for which
there is suggestive evidence of a possible autoimmune mechanism.
In addition, people with fibromyalgia and chronic fatigue syndrome have
had marked improvement using LDN, suggesting that these entities
probably have an important autoimmune dynamic as well.
Recent Developments
> Parkinson's Disease
As of September 2003, Dr. Bihari reported that there were seven
patients with Parkinson's Disease (PD) in his practice, all of whom
have shown no progression since beginning LDN. Indeed, two of them have
shown clear evidence of improvement in signs and symptoms.
Two people with PD, the first patients with that disorder known to have
been treated with LDN, have had good results that persist after more
than two years on LDN. One patient, a man in his mid-60's from New
Jersey, had his first annual revisit to Dr. Bihari for a check-up in
April 2002. His wife reported that, in contrast to all the other
members of his PD monthly group meeting, he seemed to have shown no
deterioration in his functional abilities throughout the prior year. On
a thorough neurological examination, Dr. Bihari found improvement in
some signs of his Parkinson's Disease. Among these was now the absence
of the glabellar sign, a primitive reflex that is consistently found in
those with PD and which the patient had demonstrated the year before on
his initial examination.
Another patient with PD is a 48-year-old male who began LDN in December
2000. Because he was seeing no improvement in his condition (although
he wasn't getting any worse), he discontinued LDN in early March 2002.
He called Bihari in mid-May 2002 because he was now beginning to see,
for the first time in over a year, worsening of his PD symptoms. In
those three months, the disease manifested increased tremor and
rigidity in the involved arm. He resumed LDN and over the following two
months experienced reversal of the progression that had occurred off of
the drug. He was also able to reduce his dopamine-analogue medication
by two-thirds, relieving the depression that it was producing.
> Amyotrophic Lateral Sclerosis
In the spring of 2002, several people with amyotrophic lateral
sclerosis, after reading the material about multiple sclerosis on this
website, asked their physicians to prescribe LDN for their ALS. Two
patients with advanced disease showed significant improvement in their
breathing, as measured by a forced vital capacity (FVC). One had a 25%
improvement within two months of beginning LDN and the other 11%
improvement. A third patient who also has advanced ALS and an impaired
FVC has had significant subjective improvement in his ability to
breathe and a reduction in his resting pulse from 96 to the low 80's.
Subsequently, in early fall 2002, the first patient, who had been
taking only 3mg of LDN nightly, notified us that both his FVC and that
of the second patient, who was using the 4.5mg dose, had reverted to
their usual baseline capacities, but that their FVC's appeared to be
remaining stable for a prolonged period.
[Ed. Note: Given the repeated demonstration of LDN's efficacy in
halting progression in virtually all cases of MS (see LDN and MS), and
the possibility of its having a therapeutic effect in Parkinson's
Disease and in ALS, it may be timely to consider LDN in treating the
full spectrum of neurodegenerative diseases whose etiology is
unknown—all of which may well have a significant underpinning of
immunodeficiency/autoimmunity causing their neurological syndromes.
Alzheimer's disease also suggests itself as an important possibility.]
--
The Silver List is a moderated forum for discussing Colloidal Silver.
Instructions for unsubscribing are posted at: http://silverlist.org
To post, address your message to: silver-list@eskimo.com
Address Off-Topic messages to: silver-off-topic-l...@eskimo.com
The Silver List and Off Topic List archives are currently down...
List maintainer: Mike Devour <mdev...@eskimo.com>
